FDA Will Give Drugs The REMS They Need, Even If Sponsors Propose Too Much
Executive Summary
Companies should not be concerned about designing Risk Evaluation and Mitigations Strategies on their own as a pre-emptive move to avoid delays in the review process, because FDA will tailor a REMS based on the product's profile, even downgrading a REMS if the sponsor's proposal is more restrictive than the agency deems appropriate